mTOR and Adipose Tissue Inflammation

NCT ID: NCT02881697

Last Updated: 2019-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-09-27

Study Completion Date

2019-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The target of rapamycin complex 2 (TORC2) is an evolutionarily conserved serine/threonine protein kinase that controls growth and metabolism. In mammals (including humans), mammalian TOR complex 2(mTORC2) contains mammalian TOR (mTOR), RICTOR, mSIN1 protein, and mLST8 gene. In an animal model, the adipose-specific rictor knockout (AdRiKO) mouse, systemic insulin resistance, hepatic steatosis, and cardiovascular dysfunction develop upon high fat diet (HFD)-induced obesity or aging. To find a molecular link between adipose mTORC2 and systemic insulin resistance, investigators have already performed transcriptomics and proteomics analysis on visceral white adipose tissue in a mouse model. The aim of the study is to confirm a molecular link between adipose mTORC2 and systemic insulin resistance in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese insulin-resistant subjects

Adipose tissue sampling in obese volunteers (BMI \> 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery

Adipose tissue sampling

Intervention Type OTHER

Lean insulin-sensitive controls

Adipose tissue sampling in normal weight patients (BMI \< 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery

Adipose tissue sampling

Intervention Type OTHER

Obese diabetic subjects

Adipose tissue sampling in obese volunteers (BMI \> 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery

Adipose tissue sampling

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adipose tissue sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obese volunteers (BMI \> 35kg/m2) aged 18 to a maximum of 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery.
* Normal weight patients (BMI \< 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery.

Exclusion Criteria

* Known diabetes mellitus
* Chronic inflammatory disease (inflammatory bowel disease, rheumatoid disease, cancer)
* Acute inflammatory disease
* Known renal disease: kidney failure
* Pregnancy:
* history of gastrointestinal surgery with major changes to the gastrointestinal tract (removal of stomach, any GI-bypass)
* Substance abuse, alcohol abuse
* Inability to follow procedures due to psychological disorders, dementia
* insufficient knowledge of project language (German)
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Beglinger, MD

Role: STUDY_CHAIR

St. Claraspital klinische Forschungsabteilung

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

mTOR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Risk of Metabolic Adaptation After Weight Loss
NCT05139420 ACTIVE_NOT_RECRUITING NA